Blog: AXIM BIOTECHNOLOGIES, INC. : Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K) –

Item 1.01 Entry into a Material Definitive Agreement.

On September 19, 2022, AXIM Biotechnologies, Inc. (“AXIM”) issued a press
release which announced that AXIM had entered into a five (5) year License and
Distribution Agreement (“Agreement”) with Verséa Ophthalmics, LLC (“Verséa”) for
the global sale and distribution of its proprietary ocular diagnostic solutions.

The Agreement provides Verséa with the exclusive right to commercialize AXIM’s
proprietary portfolio of point-of-care lab tests as well as its associated
reader and includes three of AXIM’s key biomarker tests: the Ocular
Immunoglobulin E (IgE) test, the Lactoferrin test, and the future MMP-9 test.
Each test is designed for use at the point of care and is read by AXIM’s
associated test reader system. Each test requires the collection of 0.5
microliters in tears and provides quantitative results in under 10 minutes, an
industry-leading return time. Verséa plans to launch both the novel IgE and
Lactoferrin tests at the 2022 American Academy of Ophthalmology and Optometry
conferences. The MMP-9 test is anticipated to follow in the next 18-24 months.
The to comply with the terms of the Agreement, Verséa must satisfy specified
annual minimum sales commitments and product purchases.

Item 7.01 Regulation FD Disclosure

The information set forth under this Item 7.01, including Exhibit 99.1, is being
furnished and, as a result, such information shall not be deemed “filed” for
purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the
“Exchange Act”), or otherwise subject to the liabilities of such Section, nor
shall such information be deemed incorporated by reference in any filing under
the Securities Act of 1933, as amended, or the Exchange Act, except as expressly
set forth by specific reference in such a filing.

Item 9.01 – Financial Statements and Exhibits

(d) Exhibits

Exhibit #   Description

10.1          September 15, 2022, License and Distribution Agreement by and between
            AXIM Biotechnologies, Inc. and Verséa Ophthalmics, LLC [Portions have
            been omitted]

99.1          Press Release

© Edgar Online, source Glimpses

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s